サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1713170

皮膚糸状菌症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 336 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
皮膚糸状菌症治療の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月22日
発行: Persistence Market Research
ページ情報: 英文 336 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • 皮膚糸状菌症治療の市場規模：70億7,470万米ドル（2025年）
  • 予測される市場金額：106億280万米ドル（2032年）
  • 世界市場の成長率：6.0%（2025年～2032年のCAGR）

皮膚糸状菌症治療市場 - レポート範囲

皮膚糸状菌症治療は、皮膚糸状菌によって引き起こされる一般的な爪の真菌感染症を指します。この疾患は爪の変色、肥厚、剥離を引き起こし、しばしば痛みや不快感を伴います。皮膚糸状菌症治療市場には、外用・経口抗真菌薬、レーザー治療、併用療法などのさまざまな治療オプションがあります。治療市場には、処方に基づくものとOTCの両方があり、臨床と家庭の両方の環境で使用されています。爪真菌症に対する意識の高まりと医療アクセスの向上が、市場拡大の促進要因となっています。ドラッグデリバリー手法の技術的進歩や、より安全で効果的な治療法の開発が、患者のコンプライアンスを高め、市場の魅力を高めています。

市場成長の促進要因

世界の皮膚糸状菌症治療市場は、特に老年人口、糖尿病患者、免疫力が低下した患者における真菌性爪感染症の罹患率の上昇などのさまざまな要因によって牽引されています。また、足の衛生に対する意識の高まりや、爪の見た目を美しくしたいという需要も、市場成長に寄与しています。さらに、テルビナフィンやイトラコナゾールなどの標的抗真菌療法が利用可能になりつつあることや、外用薬剤の進歩により、治療効果が大幅に向上しています。また、遠隔皮膚科やデジタルヘルスプラットフォームの拡大により、特に遠隔地や医療が行き届いていない地域で診断率や治療率がさらに向上しています。

市場抑制要因

有望な成長見通しにもかかわらず、市場は複数の課題に直面しています。感染症の再発、治療期間の長期化、患者の服薬コンプライアンス違反は依然として大きな懸念事項です。特定の処方による治療が高額であることや、地域によっては保険適用が限られていることが、治療へのアクセスを妨げています。さらに、肝毒性などの全身性抗真菌薬に伴う副作用は、注意深い患者のモニタリングを必要とするため、患者と医療提供者の双方に負担をかける可能性があります。また、製品承認への規制上のハードルや長期にわたる臨床試験の必要性も、新規参入企業にとって市場参入の障壁となっています。

市場機会

皮膚糸状菌症治療市場には、技術革新と臨床アンメットニーズによってもたらされる多くの成長機会があります。浸透力が強化され毒性が低減された新しい抗真菌薬の開発は、製薬企業の重点分野です。さらに、レーザーを用いた光線力学的療法の人気が高まっており、副作用の少ない非侵襲的な代替の治療法が提案されています。研究開発への投資の増加と、製薬企業と皮膚科クリニックの戦略的提携により、次世代治療の導入が促進されると予測されます。新興経済国は、可処分所得の増加、都市化、医療インフラの改良により、未開発の可能性を秘めています。

当レポートでは、世界の皮膚糸状菌症治療市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 規制情勢
  • 治療採用分析
  • 疾病の疫学
  • パイプライン分析
  • 償還シナリオ
  • バリューチェーン分析
  • 主な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の皮膚糸状菌症治療市場の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界の皮膚糸状菌症治療市場の見通し：治療タイプ
    • イントロダクション/主な調査結果
    • 市場規模分析：治療タイプ別（2019年～2024年）
    • 現在の市場規模の分析と予測：治療タイプ別（2025年～2032年）
      • 薬物療法
        • 外用抗真菌薬
        • 経口抗真菌薬
      • レーザー療法
      • 光線力学療法
      • 併用療法
    • 市場の魅力分析：治療タイプ
  • 世界の皮膚糸状菌症治療市場の見通し：適応症
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：適応症別（2019年～2024年）
    • 現在の市場規模の分析と予測：適応症別（2025年～2032年）
      • 遠位爪下爪真菌症
      • 表在性白色爪真菌症
      • 近位爪下爪真菌症
      • カンジダ性爪真菌症
      • 全異栄養性爪真菌症
    • 市場の魅力分析：適応症
  • 世界の皮膚糸状菌症治療市場の見通し：エンドユーザー
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：エンドユーザー別（2019年～2024年）
    • 現在の市場規模の分析と予測：エンドユーザー別（2025年～2032年）
      • 機関販売
        • 病院
        • 皮膚科クリニック
      • 小売販売
        • 小売薬局
        • ドラッグストア
        • 通信販売薬局・オンライン販売
    • 市場の魅力分析：エンドユーザー

第5章 世界の皮膚糸状菌症治療市場の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の皮膚糸状菌症治療市場の見通し

第7章 欧州の皮膚糸状菌症治療市場の見通し

第8章 東アジアの皮膚糸状菌症治療市場の見通し

第9章 南アジア・オセアニアの皮膚糸状菌症治療市場の見通し

第10章 ラテンアメリカの皮膚糸状菌症治療市場の見通し

第11章 中東・アフリカの皮膚糸状菌症治療市場の見通し

第12章 競合情勢

  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • Bausch Health
    • Galderma SA
    • Novartis AG
    • Pfizer, Inc.
    • Moberg Pharma AB
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Ltd.
    • Medimetriks Pharmaceuticals, Inc.
    • Sanofi SA
    • GlaxoSmithKline Plc.
    • Teva Pharmaceutical industries Ltd.
    • Cardinal Health Inc.
    • Viatris Inc.
    • Almirall, SA
    • Vanda Pharmaceuticals Inc.
    • その他

第13章 付録

目次
Product Code: PMRREP5840

Persistence Market Research has recently released a comprehensive report on the worldwide market for dermatophytic onychomycosis therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global dermatophytic onychomycosis therapeutics market from 2025 to 2032.

Key Insights:

  • Dermatophytic Onychomycosis Therapeutics Market Size (2025E): USD 7,074.7 Million
  • Projected Market Value (2032F): USD 10,602.8 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.0%

Dermatophytic Onychomycosis Therapeutics Market - Report Scope:

Dermatophytic onychomycosis refers to a common fungal infection of the nail caused by dermatophytes. This condition leads to nail discoloration, thickening, and detachment, often accompanied by pain and discomfort. The market for dermatophytic onychomycosis therapeutics includes a variety of treatment options such as topical and oral antifungal agents, laser therapy, and combination treatments. The therapeutic market caters to both prescription-based and over-the-counter (OTC) products across clinical and home settings. Increasing prevalence of nail fungal infections, coupled with growing awareness and improved healthcare access, is driving market expansion. Technological advancements in drug delivery methods and the development of safer and more effective treatment options are enhancing patient compliance and market appeal.

Market Growth Drivers:

The global dermatophytic onychomycosis therapeutics market is driven by a range of factors, including the rising incidence of fungal nail infections, particularly among the aging population, diabetic patients, and individuals with compromised immune systems. Increasing awareness of foot hygiene and the demand for aesthetic nail appearance are also contributing to market growth. Furthermore, the growing availability of targeted antifungal therapies, such as terbinafine and itraconazole, and advancements in topical drug formulations have significantly improved treatment efficacy. The expansion of teledermatology and digital health platforms has further boosted diagnosis rates and treatment uptake, particularly in remote and underserved regions.

Market Restraints:

Despite promising growth prospects, the market faces several challenges. Recurrence of infection, lengthy treatment durations, and patient non-compliance with medication regimens remain significant concerns. The high cost of certain prescription treatments and limited insurance coverage in some regions can hinder access to therapy. In addition, side effects associated with systemic antifungal medications, such as liver toxicity, require careful patient monitoring, which may deter both patients and providers. Regulatory hurdles for product approval and the need for long-term clinical trials also pose barriers to market entry for new players.

Market Opportunities:

The dermatophytic onychomycosis therapeutics market offers numerous growth opportunities driven by innovation and unmet clinical needs. The development of novel antifungal agents with enhanced penetration and reduced toxicity is a key area of focus for pharmaceutical companies. Additionally, the rising popularity of laser-based and photodynamic therapies presents non-invasive alternatives with minimal side effects. Increased investment in R&D, combined with strategic collaborations between pharmaceutical companies and dermatology clinics, is expected to foster the introduction of next-generation treatments. Emerging economies present untapped potential due to rising disposable income, urbanization, and improving healthcare infrastructure.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the dermatophytic onychomycosis therapeutics market globally?
  • Which treatment modalities are gaining traction among patients and providers across various healthcare settings?
  • How are technological innovations impacting treatment effectiveness and patient adherence in onychomycosis management?
  • Who are the major players in this therapeutic space, and what strategies are they adopting to maintain competitiveness?
  • What are the upcoming trends and future outlook for the global dermatophytic onychomycosis therapeutics market?

Competitive Intelligence and Business Strategy:

Key players in the global dermatophytic onychomycosis therapeutics market, including Pfizer Inc., Novartis AG, Bausch Health Companies Inc., and Moberg Pharma AB, focus on expanding their product portfolios through R&D, strategic partnerships, and geographical expansion. Companies are also investing in developing user-friendly topical treatments and oral medications with shorter treatment durations and improved efficacy. Collaborations with dermatology clinics and retail pharmacies, along with patient education campaigns, are enhancing awareness and improving treatment outcomes. Digital marketing and e-commerce platforms are increasingly leveraged to improve product accessibility and consumer reach.

Key Companies Profiled:

  • Bausch Health
  • Galderma S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Moberg Pharma AB
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Medimetriks Pharmaceuticals, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Cardinal Health Inc.
  • Viatris Inc.
  • Almirall, S.A
  • Vanda Pharmaceuticals Inc.
  • Others

Market Segmentation

By Treatment Type

  • Drug-Based Treatment

* Topical Antifungals

* Oral Antifungals

  • Laser Therapy
  • Photodynamic Therapy
  • Combination Therapy

By Indication

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By End-user

  • Institutional Sales
  • Hospitals
  • Dermatology Clinics
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Treatment Adoption Analysis
  • 3.3. Disease Epidemiology
  • 3.4. Pipeline Analysis
  • 3.5. Reimbursement Scenario
  • 3.6. Value Chain Analysis
  • 3.7. Key Deals and Mergers
  • 3.8. PESTLE Analysis
  • 3.9. Porter's Five Force Analysis

4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Treatment Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
      • 4.3.3.1. Drug-Based Treatment
        • 4.3.3.1.1. Topical Antifungals
        • 4.3.3.1.2. Oral Antifungals
      • 4.3.3.2. Laser Therapy
      • 4.3.3.3. Photodynamic Therapy
      • 4.3.3.4. Combination Therapy
    • 4.3.4. Market Attractiveness Analysis: Treatment Type
  • 4.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.4.3.1. Distal Subungual Onychomycosis
      • 4.4.3.2. White Superficial Onychomycosis
      • 4.4.3.3. Proximal Subungual Onychomycosis
      • 4.4.3.4. Candidal Onychomycosis
      • 4.4.3.5. Total Dystrophic Onychomycosis
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Institutional Sales
        • 4.5.3.1.1. Hospitals
        • 4.5.3.1.2. Dermatology Clinics
      • 4.5.3.2. Retail Sales
        • 4.5.3.2.1. Retail Pharmacies
        • 4.5.3.2.2. Drug Stores
        • 4.5.3.2.3. Mail Order Pharmacies & Online Sales
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Treatment Type
    • 6.2.3. By Indication
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 6.4.1. Drug-Based Treatment
      • 6.4.1.1. Topical Antifungals
      • 6.4.1.2. Oral Antifungals
    • 6.4.2. Laser Therapy
    • 6.4.3. Photodynamic Therapy
    • 6.4.4. Combination Therapy
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.5.1. Distal Subungual Onychomycosis
    • 6.5.2. White Superficial Onychomycosis
    • 6.5.3. Proximal Subungual Onychomycosis
    • 6.5.4. Candidal Onychomycosis
    • 6.5.5. Total Dystrophic Onychomycosis
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Institutional Sales
      • 6.6.1.1. Hospitals
      • 6.6.1.2. Dermatology Clinics
    • 6.6.2. Retail Sales
      • 6.6.2.1. Retail Pharmacies
      • 6.6.2.2. Drug Stores
      • 6.6.2.3. Mail Order Pharmacies & Online Sales
  • 6.7. Market Attractiveness Analysis

7. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Treatment Type
    • 7.2.3. By Indication
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 7.4.1. Drug-Based Treatment
      • 7.4.1.1. Topical Antifungals
      • 7.4.1.2. Oral Antifungals
    • 7.4.2. Laser Therapy
    • 7.4.3. Photodynamic Therapy
    • 7.4.4. Combination Therapy
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.5.1. Distal Subungual Onychomycosis
    • 7.5.2. White Superficial Onychomycosis
    • 7.5.3. Proximal Subungual Onychomycosis
    • 7.5.4. Candidal Onychomycosis
    • 7.5.5. Total Dystrophic Onychomycosis
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Institutional Sales
      • 7.6.1.1. Hospitals
      • 7.6.1.2. Dermatology Clinics
    • 7.6.2. Retail Sales
      • 7.6.2.1. Retail Pharmacies
      • 7.6.2.2. Drug Stores
      • 7.6.2.3. Mail Order Pharmacies & Online Sales
  • 7.7. Market Attractiveness Analysis

8. East Asia Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Treatment Type
    • 8.2.3. By Indication
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 8.4.1. Drug-Based Treatment
      • 8.4.1.1. Topical Antifungals
      • 8.4.1.2. Oral Antifungals
    • 8.4.2. Laser Therapy
    • 8.4.3. Photodynamic Therapy
    • 8.4.4. Combination Therapy
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.5.1. Distal Subungual Onychomycosis
    • 8.5.2. White Superficial Onychomycosis
    • 8.5.3. Proximal Subungual Onychomycosis
    • 8.5.4. Candidal Onychomycosis
    • 8.5.5. Total Dystrophic Onychomycosis
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Institutional Sales
      • 8.6.1.1. Hospitals
      • 8.6.1.2. Dermatology Clinics
    • 8.6.2. Retail Sales
      • 8.6.2.1. Retail Pharmacies
      • 8.6.2.2. Drug Stores
      • 8.6.2.3. Mail Order Pharmacies & Online Sales
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Treatment Type
    • 9.2.3. By Indication
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 9.4.1. Drug-Based Treatment
      • 9.4.1.1. Topical Antifungals
      • 9.4.1.2. Oral Antifungals
    • 9.4.2. Laser Therapy
    • 9.4.3. Photodynamic Therapy
    • 9.4.4. Combination Therapy
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.5.1. Distal Subungual Onychomycosis
    • 9.5.2. White Superficial Onychomycosis
    • 9.5.3. Proximal Subungual Onychomycosis
    • 9.5.4. Candidal Onychomycosis
    • 9.5.5. Total Dystrophic Onychomycosis
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Institutional Sales
      • 9.6.1.1. Hospitals
      • 9.6.1.2. Dermatology Clinics
    • 9.6.2. Retail Sales
      • 9.6.2.1. Retail Pharmacies
      • 9.6.2.2. Drug Stores
      • 9.6.2.3. Mail Order Pharmacies & Online Sales
  • 9.7. Market Attractiveness Analysis

10. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Treatment Type
    • 10.2.3. By Indication
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 10.4.1. Drug-Based Treatment
      • 10.4.1.1. Topical Antifungals
      • 10.4.1.2. Oral Antifungals
    • 10.4.2. Laser Therapy
    • 10.4.3. Photodynamic Therapy
    • 10.4.4. Combination Therapy
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.5.1. Distal Subungual Onychomycosis
    • 10.5.2. White Superficial Onychomycosis
    • 10.5.3. Proximal Subungual Onychomycosis
    • 10.5.4. Candidal Onychomycosis
    • 10.5.5. Total Dystrophic Onychomycosis
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Institutional Sales
      • 10.6.1.1. Hospitals
      • 10.6.1.2. Dermatology Clinics
    • 10.6.2. Retail Sales
      • 10.6.2.1. Retail Pharmacies
      • 10.6.2.2. Drug Stores
      • 10.6.2.3. Mail Order Pharmacies & Online Sales
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Treatment Type
    • 11.2.3. By Indication
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 11.4.1. Drug-Based Treatment
      • 11.4.1.1. Topical Antifungals
      • 11.4.1.2. Oral Antifungals
    • 11.4.2. Laser Therapy
    • 11.4.3. Photodynamic Therapy
    • 11.4.4. Combination Therapy
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.5.1. Distal Subungual Onychomycosis
    • 11.5.2. White Superficial Onychomycosis
    • 11.5.3. Proximal Subungual Onychomycosis
    • 11.5.4. Candidal Onychomycosis
    • 11.5.5. Total Dystrophic Onychomycosis
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Institutional Sales
      • 11.6.1.1. Hospitals
      • 11.6.1.2. Dermatology Clinics
    • 11.6.2. Retail Sales
      • 11.6.2.1. Retail Pharmacies
      • 11.6.2.2. Drug Stores
      • 11.6.2.3. Mail Order Pharmacies & Online Sales
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Structure
    • 12.1.1. Competition Intensity Mapping By Market
    • 12.1.2. Competition Dashboard
  • 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.2.1. Bausch Health
      • 12.2.1.1. Overview
      • 12.2.1.2. Segments and Treatment Types
      • 12.2.1.3. Key Financials
      • 12.2.1.4. Market Developments
      • 12.2.1.5. Market Strategy
    • 12.2.2. Galderma S.A.
    • 12.2.3. Novartis AG
    • 12.2.4. Pfizer, Inc.
    • 12.2.5. Moberg Pharma AB
    • 12.2.6. Bayer AG
    • 12.2.7. Dr. Reddy's Laboratories Ltd.
    • 12.2.8. Cipla Ltd.
    • 12.2.9. Medimetriks Pharmaceuticals, Inc.
    • 12.2.10. Sanofi S.A.
    • 12.2.11. GlaxoSmithKline Plc.
    • 12.2.12. Teva Pharmaceutical industries Ltd.
    • 12.2.13. Cardinal Health Inc.
    • 12.2.14. Viatris Inc.
    • 12.2.15. Almirall, S.A
    • 12.2.16. Vanda Pharmaceuticals Inc.
    • 12.2.17. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations